Kite and Gadeta announce strategic collaboration to advance gamma delta T cell receptor
Kite, a Gilead Company, and Gadeta B.V. have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers. Kite will provide R&D funding and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones. July 19, 2018